Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III observer-masked study of STN1014003 vs latanoprost in open-angle glaucoma/ocular hypertension with long-term open-label extension
jRCT2031240688Phase 3Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of sepetaprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Mean diurnal intraocular pressure at Week 4. Started Mar 2025; status: recruiting.
02
Drugs
sepetaprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031240688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240688.